Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) Operating Expenses (2016 - 2025)

Celldex Therapeutics has reported Operating Expenses over the past 16 years, most recently at $87.3 million for Q4 2025.

  • Quarterly results put Operating Expenses at $87.3 million for Q4 2025, up 52.57% from a year ago — trailing twelve months through Dec 2025 was $288.9 million (up 42.96% YoY), and the annual figure for FY2025 was $288.9 million, up 42.96%.
  • Operating Expenses for Q4 2025 was $87.3 million at Celldex Therapeutics, up from $73.6 million in the prior quarter.
  • Over the last five years, Operating Expenses for CLDX hit a ceiling of $87.3 million in Q4 2025 and a floor of $16.9 million in Q2 2021.
  • Median Operating Expenses over the past 5 years was $38.7 million (2022), compared with a mean of $42.3 million.
  • Biggest five-year swings in Operating Expenses: fell 27.63% in 2021 and later skyrocketed 116.07% in 2022.
  • Celldex Therapeutics' Operating Expenses stood at $20.7 million in 2021, then skyrocketed by 42.68% to $29.5 million in 2022, then surged by 75.46% to $51.8 million in 2023, then rose by 10.52% to $57.2 million in 2024, then soared by 52.57% to $87.3 million in 2025.
  • The last three reported values for Operating Expenses were $87.3 million (Q4 2025), $73.6 million (Q3 2025), and $64.6 million (Q2 2025) per Business Quant data.